Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy
Yasmin Schmid, Anya K. Bershad
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 9, 2024 DOI: 10.1016/j.bpsc.2024.02.001 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative overview Peer reviewed |
|---|---|
| Topics | MDMA Serotonin Psychedelic-assisted therapy |
| Keywords | Prosocial behavior Hallucinogen Social defeat |
| Citations | 15 |
| Key points | MDMA and serotonergic psychedelics both produce prosocial effects but differ in the mechanisms through which they do so, affecting the types of psychosocial interventions that may work best with each compound. |
Abstract
There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple psychiatric disorders. Many of these compounds are known to produce prosocial effects, but how these effects relate to therapeutic efficacy and the extent to which prosocial effects are unique to a particular drug class is unknown. In this article, we present a narrative overview and compare evidence for the prosocial effects of MDMA and serotonergic psychedelics to elucidate shared mechanisms that may underlie the therapeutic process. We discuss 4 categories of prosocial effects: altered self-image, responses to social reward, responses to negative social input, and social neuroplasticity. While both categories of drugs alter self-perception, MDMA may do so in a way that is less related to the experience of mystical-type states than serotonergic psychedelics. In the case of social reward, evidence supports the ability of MDMA to enhance responses and suggests that serotonergic psychedelics may also do so, but more research is needed in this area. Both drug classes consistently dampen reactivity to negative social stimuli. Finally, preclinical evidence supports the ability of both drug classes to induce social neuroplasticity, promoting adaptive rewiring of neural circuits, which may be helpful in trauma processing. While both MDMA and serotonergic psychedelics produce prosocial effects, they differ in the mechanisms through which they do this. These differences affect the types of psychosocial interventions that may work best with each compound.
Citations in the library
Cited by 13
- Trauma Under Psychedelics: How Psychoactive Substances Impact Trauma Processing bioRxiv Preprint Server March 28, 2024
- Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories. Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025
- Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats. Scientific Reports May 26, 2025
- Relationality and Ethics in MDMA-Assisted Therapy. The American Journal of Bioethics January 13, 2025
- Ayahuasca Enhances Functional Connectivity in the Third Visual Pathway and Mirror Neuron Networks: a Crossover, Multiple-Dose fMRI Study. Social Cognitive and Affective Neuroscience January 31, 2026
and 8 more in the library
Cites 102
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 97 more in the library